发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Patent highlights April-May 2020. 2020 年 4 月至 5 月的专利要点。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2020-09-01 Epub Date: 2020-09-22 DOI: 10.4155/ppa-2020-0018
Hermann Am Mucke
{"title":"Patent highlights April-May 2020.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2020-0018","DOIUrl":"10.4155/ppa-2020-0018","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 5","pages":"139-146"},"PeriodicalIF":1.8,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38502607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Three drugs facing key patent expirations and potential generic entry from September to October 2020. 2020年9月至10月，三种药物面临关键专利到期和可能进入仿制药市场。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-09-01 Epub Date: 2020-10-22 DOI: 10.4155/ppa-2020-0029
Yali Friedman
{"title":"Three drugs facing key patent expirations and potential generic entry from September to October 2020.","authors":"Yali Friedman","doi":"10.4155/ppa-2020-0029","DOIUrl":"https://doi.org/10.4155/ppa-2020-0029","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 5","pages":"147-148"},"PeriodicalIF":1.3,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/ppa-2020-0029","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38620386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors. 晚期实体瘤双特异性抗pd -1/CTLA-4抗体。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-09-01 Epub Date: 2020-09-22 DOI: 10.4155/ppa-2020-0017
Martin Perez-Santos
{"title":"Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors.","authors":"Martin Perez-Santos","doi":"10.4155/ppa-2020-0017","DOIUrl":"https://doi.org/10.4155/ppa-2020-0017","url":null,"abstract":"<p><p>PD-1 and CTLA-4 are checkpoint inhibitors of the immune response in cancer, making them the target molecules for the development of therapeutic antibodies. US2019161548 patent describes a bispecific antibody capable of specifically binding to PD-1 and CTLA-4 that induced the proliferation and activation of CD8<sup>+</sup> cells, as well as the expression of induclble co-stimulator in CD4<sup>+</sup> T cells. Clinical trials to evaluate safety, dose-limiting toxicities and maximum tolerated/administered dose are still in the patient recruitment phase, but it will be of great interest to the scientific and medical community to know if the first bispecific anti-PD-1/CLTA-4 antibody, exceeds expectations and exceeds action of the combination of nivolumab and epilimumab in the treatment of cancer.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 5","pages":"149-154"},"PeriodicalIF":1.3,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38405228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Two drugs facing key patent expirations and potential generic entry from July to August 2020. 2020年7月至8月，两种药物面临关键专利到期和可能进入仿制药市场。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-07-01 DOI: 10.4155/ppa-2020-0021
Yali Friedman
{"title":"Two drugs facing key patent expirations and potential generic entry from July to August 2020.","authors":"Yali Friedman","doi":"10.4155/ppa-2020-0021","DOIUrl":"https://doi.org/10.4155/ppa-2020-0021","url":null,"abstract":"<p><p>A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 4","pages":"137-138"},"PeriodicalIF":1.3,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/ppa-2020-0021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38279695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights February-March 2020. 2020 年 2 月至 3 月的专利要点。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2020-07-01 DOI: 10.4155/ppa-2020-0010
Hermann Am Mucke
{"title":"Patent highlights February-March 2020.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2020-0010","DOIUrl":"10.4155/ppa-2020-0010","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 4","pages":"129-136"},"PeriodicalIF":1.8,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38279696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patents in chemotherapy: nanoparticles as drug-delivery vehicles. 化疗专利:纳米粒子作为药物输送载体。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-07-01 DOI: 10.4155/ppa-2020-0014
Absar Talat, Asad U Khan
{"title":"Patents in chemotherapy: nanoparticles as drug-delivery vehicles.","authors":"Absar Talat,&nbsp;Asad U Khan","doi":"10.4155/ppa-2020-0014","DOIUrl":"https://doi.org/10.4155/ppa-2020-0014","url":null,"abstract":"<p><p>The high statistics of cancer cases and mortalities throughout the world signify the urgent need for an advanced technology to target tumor cells. Nanotechnology has emerged as one such revolutionary platform to specifically target cancerous tissues and to enhance the efficacy for various anticancer drugs. This report is a snapshot of the patents in chemotherapy from January 2010 to May 2020 involving nanoparticles, novel methods developed for their synthesis and their impact as efficient drug-delivery vehicles.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 4","pages":"117-119"},"PeriodicalIF":1.3,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/ppa-2020-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38279692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Current treatment options of Balamuthia mandrillaris: a patent overview. 目前的治疗方案的曼陀罗:专利概述。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-07-01 DOI: 10.4155/ppa-2020-0016
Ruqaiyyah Siddiqui, Naveed A Khan
{"title":"Current treatment options of <i>Balamuthia mandrillaris</i>: a patent overview.","authors":"Ruqaiyyah Siddiqui,&nbsp;Naveed A Khan","doi":"10.4155/ppa-2020-0016","DOIUrl":"https://doi.org/10.4155/ppa-2020-0016","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 4","pages":"121-123"},"PeriodicalIF":1.3,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/ppa-2020-0016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38279693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Current strategies to treat Acanthamoeba keratitis: a patent overview. 目前治疗棘阿米巴角膜炎的策略:专利概述。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-07-01 DOI: 10.4155/ppa-2020-0020
Ruqaiyyah Siddiqui, Naveed A Khan
{"title":"Current strategies to treat <i>Acanthamoeba</i> keratitis: a patent overview.","authors":"Ruqaiyyah Siddiqui,&nbsp;Naveed A Khan","doi":"10.4155/ppa-2020-0020","DOIUrl":"https://doi.org/10.4155/ppa-2020-0020","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 4","pages":"125-127"},"PeriodicalIF":1.3,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/ppa-2020-0020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38279694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Sigma-1 receptor antagonists: promising players in fighting neuropathic pain. Sigma-1受体拮抗剂：对抗神经性疼痛的希望之源
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-05-01 Epub Date: 2020-06-16 DOI: 10.4155/ppa-2020-0007
Pasquale Linciano, Giacomo Rossino, Roberta Listro, Daniela Rossi, Simona Collina
{"title":"Sigma-1 receptor antagonists: promising players in fighting neuropathic pain.","authors":"Pasquale Linciano, Giacomo Rossino, Roberta Listro, Daniela Rossi, Simona Collina","doi":"10.4155/ppa-2020-0007","DOIUrl":"10.4155/ppa-2020-0007","url":null,"abstract":"<p><p>Sigma-1 receptors (S1Rs) are strongly correlated to neuropathic pain (NP), since their inactivation may decrease allodynia or dysesthesia, promoting analgesic effects. In the recent patent landscape, S1R antagonists endowed with nanomolar S1Rs affinity emerged as potent antinociceptive agents. So far, three patented compounds have been proposed for counteracting NP. Particularly <b>PV-752</b> and <b>AV1066</b>, disclosed by the University of Pavia (Italy) and Anavex, respectively, showed good analgesic activity in preclinical studies. Moreover, <b>E-52862</b> developed by Esteve (Spain) has been proved to be effective, both in preclinical and Phase II clinical trials, against several symptoms of NP. These patents ascertain S1R antagonists as potential drugs, alone or in combination with other analgesic drugs, for managing NP in humans.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 3","pages":"77-85"},"PeriodicalIF":1.3,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/ppa-2020-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38047588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Small-molecule inhibitors of α-synuclein for the treatment of Parkinson's disease: a patent landscape. α-突触核蛋白小分子抑制剂治疗帕金森病:专利景观
IF 1.3
Pharmaceutical patent analyst Pub Date : 2020-05-01 Epub Date: 2020-06-30 DOI: 10.4155/ppa-2020-0008
Jacques Joubert
{"title":"Small-molecule inhibitors of α-synuclein for the treatment of Parkinson's disease: a patent landscape.","authors":"Jacques Joubert","doi":"10.4155/ppa-2020-0008","DOIUrl":"https://doi.org/10.4155/ppa-2020-0008","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"9 3","pages":"63-65"},"PeriodicalIF":1.3,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4155/ppa-2020-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38102012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信